TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8354332
Drug: Intravenous glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucose (35 g)
Study: 8354332
Drug: Intravenous amino
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous amino acids (10 g)
Study: 3545108
Drug: Methimazole in
Normalized name: methimazole Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole in combination with thyroxine (Group I)
Study: 12220761
Drug: Fluoxetine 10
Normalized name: fluoxetine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10 mg
Study: 11106133
Drug: Fluoxetine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (both doses)
Study: 11417777
Drug: Intranasal nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal nicotine spray
Study: 1855281
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg dexamethasone (i.v.)
Study: 7049340
Drug: Lecithin and
Normalized name: Lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithin and linoleic acid supplements
Study: 17451577
Drug: Stacked double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stacked double pulses (single-pass treatment)
Study: 17451577
Drug: Double-pass treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-pass treatment of single pulses
Study: 11641361
Drug: Technegas inhalation
Normalized name: TECHNEGAS KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technegas inhalation during tidal breathing
Study: 11641361
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine (dose sufficient to abolish expiratory flow reserve)
Study: 11641361
Drug: Three increasing
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three increasing doses of methacholine
Study: 9689551
Drug: Non-insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-insulin-dependent diabetes mellitus patients with microalbuminuria
Study: 7737258
Drug: Casodex (ICI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (ICI 176,334) 50 mg/day
Study: 7737258
Drug: Casodex (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (100 and 150 mg/day)
Study: 7737258
Drug: Casodex (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casodex (50 mg/day)
Study: 134897
Drug: Alprenolol 400
Normalized name: alprenolol
DrugBank: Alprenolol (DB00866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol 400 mg daily
Study: 23512255
Drug: New design
Approvals — FDA: no, EMA: no, PMDA: no
Description: New design implant
Study: 23512255
Drug: Traditional implant
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional implant
Study: 18086024
Drug: Probiotic lozenge
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenge with L. reuteri ATCC 55730/L. reuteri ATCC PTA 5289 (1.1 x 10(8) CFU) once daily for 10 days
Study: 8462010
Drug: Epidoxorubicin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidoxorubicin 60 mg/m2 (group A)
Study: 8462010
Drug: Epidoxorubicin 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidoxorubicin 120 mg/m2 (group B)
Study: 2941697
Drug: Phenoterol administered
Normalized name: Phenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenoterol administered after ipratropium bromide
Study: 2941697
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide administered before phenoterol
Study: 29891834
Drug: Reduced-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose tacrolimus (4.51±1.62 ng/mL)
Study: 29891834
Drug: Standard tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tacrolimus dosage (6.75±2.82 ng/mL)
Study: 27399077
Drug: EBV DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV DNA level >200 copies/mL
Study: 16189173
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml 5% glucose solution infused over 30 min after achieving hypoglycemia
Study: 16189173
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml isotonic saline infused over 30 min after achieving hypoglycemia
Study: 10657578
Drug: HMG‐CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG‐CoA reductase inhibitors in FH patients
Study: 8866634
Drug: Brofaromine 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine 75 mg
Study: 6741679
Drug: High nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High nicotine cigarettes (2.5 mg)
Study: 6741679
Drug: Medium nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium nicotine cigarettes (1.5 mg)
Study: 6741679
Drug: Low nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low nicotine cigarettes (0.5 mg)
Study: 29923286
Drug: PF-06291874 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06291874 (30 mg once daily)
Study: 29923286
Drug: PF-06291874 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06291874 (60 mg once daily)
Study: 29923286
Drug: PF-06291874 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06291874 (100 mg once daily)
Study: 29923286
Drug: PF-06291874 (30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06291874 (30, 60, or 100 mg once daily)
Study: 27661415
Drug: Ivabradine 5mg
Normalized name: IVABRADINE 5MG TAB
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine 5mg twice a day
Study: 24264372
Drug: Ibandronate (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (cumulative dose, 13.5 mg)
Study: 22398753
Drug: Spread containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread containing bioactive milk peptides IPP and VPP, and plant sterols (20 g day⁻¹ for 10 weeks)
Study: 19815048
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (Ginko T.D. Tolidaru, Iran) at a dose of 80‐120 mg/day depending on weight (80 mg/day for <30 kg and 120 mg/day for >30 kg)
Study: 19815048
Drug: Methylphenidate at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate at a dose of 20‐30 mg/day depending on weight (20 mg/day for <30 kg and 30 mg/day for >30 kg)
Study: 378574
Drug: Rifampicin-trimethoprim combination
Normalized name: rifampin / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin-trimethoprim combination (450 mg plus 120 mg twice daily)
Study: 378574
Drug: Rifampicin alone
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin alone (450 mg twice daily)
Study: 378574
Drug: Rifampicin-trimethoprim combination
Normalized name: rifampin / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin-trimethoprim combination and rifampicin alone
Study: 30906562
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Nilotinib
Study: 28323799
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics (PO)
Study: 28323799
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics (IV)
Study: 21669016
Drug: Intranasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroid plus per-oral vitamins A, C and E and selenium
Study: 21669016
Drug: Intranasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroid
Study: 19155904
Drug: 1-day nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-day nitrofurantoin regimen (100 mg capsules, taken twice daily for 1 day)
Study: 19155904
Drug: 7-day nitrofurantoin
Normalized name: Nitrofurantoin
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7-day nitrofurantoin regimen (100 mg capsules, taken twice daily for 7 days)
Study: 16716870
Drug: Ziconotide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziconotide (0.1 microg/hour starting dose, titrated to a mean dose of 0.29 microg/hour)
Study: 11571009
Drug: Medical feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical feedback vignette with medication change recommended
Study: 11571009
Drug: Medical feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical feedback vignette with no medication change recommended
Study: 9713464
Drug: GRA 1
Normalized name: Viagra 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRA 1 mg + DEX 20 mg
Study: 9713464
Drug: GRA 3
Normalized name: Allegra 30mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GRA 3 mg + DEX 20 mg
Study: 31434809
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg every 2 weeks, up to 150 mg every 2 weeks)
Study: 31434809
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SoC; atorvastatin ≥10 mg/day or rosuvastatin ≥5 mg/day)
Study: 26267590
Drug: Phenylephrine HCl
Normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine HCl 10 mg
Study: 26267590
Drug: Phenylephrine HCl
Normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine HCl 20 mg
Study: 26267590
Drug: Phenylephrine HCl
Normalized name: Phenylephrine HCl
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylephrine HCl 30 mg
Study: 21222064
Drug: Rosuvastatin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (2.5 mg daily)
Study: 19695386
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl spray (INFS) 50 to 200 microg
Study: 9626916
Drug: Orlistat 120
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120 mg three times a day (tid)
Study: 9626916
Drug: Orlistat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (all doses)
Study: 3299174
Drug: Weekly nonstress
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly nonstress testing (NST)
Study: 3299174
Drug: NST plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: NST plus weekly ultrasound evaluation
Study: 26522611
Drug: Conventional once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional once‐daily morphologic embryo screening (CS)
Study: 26522611
Drug: Conventional once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional once‐daily morphologic embryo screening (CS) with blastocyst transfers
Study: 18781483
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen 0.625 mg
Study: 9822087
Drug: Abciximab (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abciximab (bolus plus infusion)
Study: 790946
Drug: Continuous high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous high-dose aspirin (ASA) for 14 days
Study: 790946
Drug: Interrupted high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted high-dose aspirin (ASA) for 14 days
Study: 31587887
Drug: Omeprazole 80
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 80 mg/d, orally
Study: 28346154
Drug: Text message
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text message intervention (2 text messages outlining individualized bedtime goals daily for 8 weekdays)
Study: 20934897
Drug: FPG and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FPG and HbA(1c) combination
Study: 16689755
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg day(-1)
Study: 16689755
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg day(-1)
Study: 16689755
Drug: Fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 160 mg day(-1)
Study: 16689755
Drug: Quinapril 10
Normalized name: quinapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 10 mg day(-1)
Study: 16689755
Drug: All drugs
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All drugs tested (including aspirin)
Study: 15558071
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (33.3 mg m(‐2) for 6 weeks)
Study: 15558071
Drug: 3-weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly docetaxel (75 mg m(‐2))
Study: 15558071
Drug: Both weekly
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both weekly and 3-weekly docetaxel
Study: 8493629
Drug: Salbutamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (400 micrograms four times daily)
Study: 8493629
Drug: Salbutamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (400 micrograms twice daily)
Study: 30636064
Drug: Four implants
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four implants in the posterior maxilla
Study: 30636064
Drug: Six implants
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six implants in the posterior maxilla
Study: 28560762
Drug: Desmopressin 25
Normalized name: desmopressin acetate 27.7 MCG (desmopressin 25 MCG) Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 25 µg ODT + Tolterodine 4 mg (n=49)
Study: 28560762
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg (n=57)
Study: 25362163
Drug: Metoprolol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol administration
Study: 11123825
Drug: Diethyl carbamazine
Normalized name: Diethyl Phthalate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethyl carbamazine (DEC) (6 mg/kg/body weight)
Study: 8259846
Drug: Ftorafur (FT)
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ftorafur (FT) 600 mg/day for 2 years
Study: 8259846
Drug: Ftorafur (FT)
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ftorafur (FT) 600 mg/day plus Tamoxifen (TAM) 20 mg/day for 2 years
Study: 7579506
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg/day for 2 years
Study: 3964494
Drug: Phosphate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate (1.5 g/day)
Study: 3964494
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Phosphate + Calcitonin)
Study: 29239867
Drug: AZI/AML/HCTZ 20/5/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZI/AML/HCTZ 20/5/12.5 mg
Study: 29239867
Drug: AZI/AML/HCTZ 20/5/6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZI/AML/HCTZ 20/5/6.25 mg
Study: 29239867
Drug: AZI/AML 20/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZI/AML 20/5 mg
Study: 12588577
Drug: HCTZ 12.5
Normalized name: HCTZ 12.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 12.5 mg
Study: 29239867
Drug: HCTZ 6.25
Normalized name: BENAZEPRIL HCL 5/HCTZ 6.25MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 6.25 mg
Study: 25549485
Drug: High-doses of
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-doses of antithrombin III (AT)
Study: 16088081
Drug: Ferumoxytol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol at 1 mg iron/kg
Study: 16088081
Drug: Ferumoxytol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol at 2 mg iron/kg
Study: 16088081
Drug: Ferumoxytol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol at 4 mg iron/kg
Study: 16088081
Drug: Ferumoxytol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol at 4 mg iron/kg at injection rates of 90 mg/min
Study: 16088081
Drug: Ferumoxytol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol at 4 mg iron/kg at injection rates of 180 mg/min
Study: 16088081
Drug: Ferumoxytol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol at 4 mg iron/kg at injection rates of 1800 mg/min
Study: 16088081
Drug: Ferumoxytol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol at 125 mg over 5 min in hemodialysis patients
Study: 16088081
Drug: Ferumoxytol at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferumoxytol at 250 mg over 5 min in hemodialysis patients
Study: 7749431
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol of gonadotropin releasing hormone agonist (GnRH‐a) administration
Study: 7749431
Drug: Short protocol
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short protocol of gonadotropin releasing hormone agonist (GnRH‐a) administration
Study: 575498
Drug: Creatinol O-phosphate
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Creatinol O-phosphate (COP) 3.06 g i.v./24 h for 3 days
Study: 575498
Drug: Glucose-insulin-K+ (GIK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-insulin-K+ (GIK) for 3 days
Study: 25556916
Drug: Paclitaxel/carboplatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/carboplatin plus sorafenib (400 mg orally twice daily)
Study: 20350786
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen deprivation therapy (NADT) for 0, 3, or 6 months prior to and during radiation treatment at 66 Gy
Study: 19476583
Drug: LDL cholesterol
Normalized name: LDL cholesterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL cholesterol <or=130 mg/dL
Study: 19476583
Drug: LDL levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL levels between 131 and 159 mg/dL
Study: 17295586
Drug: Daily dip-evening
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily dip-evening incline cluster smoking patterns
Study: 17295586
Drug: Daily decline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily decline cluster smoking patterns
Study: 12891637
Drug: Long-acting opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting opioid therapy for 4 weeks
Study: 9198464
Drug: aceclofenac 100
Normalized name: aceclofenac 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: aceclofenac 100 mg/12 h
Study: 9198464
Drug: paracetamol 650
Normalized name: Paracetamol 650 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracetamol 650 mg/12 h
Study: 24858257
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Chinese medicine (CM) and Western medicine intervention termed optimum proposal of integration of disease and syndrome (OPIDS)
Study: 19573229
Drug: Identifying obstacles
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Identifying obstacles for RTW and formulating solutions for suitable (therapeutic) work with the help of an independent RTW coordinator.
Study: 15646911
Drug: EMLA (eutectic
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (eutectic mixture of local anesthetics, 2.5% lidocaine and 2.5% prilocaine) cream
Study: 11158042
Drug: levormeloxifene 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: levormeloxifene 1.25 mg/day
Study: 11158042
Drug: levormeloxifene 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: levormeloxifene 5 mg/day
Study: 11158042
Drug: levormeloxifene 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: levormeloxifene 10 mg/day
Study: 11158042
Drug: levormeloxifene 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: levormeloxifene 20 mg/day
Study: 11158042
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose HRT (1 mg 17 beta‐estradiol and 0.5 mg norethisterone acetate/day)
Study: 11158042
Drug: placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (500 mg calcium)
Study: 11158042
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose HRT
Study: 29635632
Drug: Hydromorphone immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:5
Study: 29635632
Drug: Hydromorphone immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone immediate-release tablets at a dose converted at a hydromorphone:morphine ratio of 1:8
Study: 25511551
Drug: Daily intravaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily intravaginal 0.50% prasterone for 2 weeks followed by twice weekly for 10 weeks
Study: 21524710
Drug: Banana consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banana consumption (one medium banana twice a day)
Study: 21524710
Drug: Banana-flavoured drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Banana-flavoured drink (one cup twice a day)
Study: 21524710
Drug: Water (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (one cup twice a day)
Study: 19505388
Drug: Pre-co-seasonal sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-co-seasonal sublingual immunotherapy with modified allergen extract
Study: 16772806
Drug: Oxycodone/Paracetamol 5/325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/Paracetamol 5/325 mg and 10/650 mg
Study: 16772806
Drug: Bromfenac 25
Normalized name: bromfenac 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 25 mg and 50 mg
Study: 15531006
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg once daily (level 1)
Study: 15531006
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg once daily (level 1)
Study: 15531006
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg once daily (level 2)
Study: 15531006
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg once daily (level 2)